Literature DB >> 34924641

SIMULTANEOUS IN VITRO SIMULATION OF MULTIPLE ANTIMICROBIAL AGENTS WITH DIFFERENT ELIMINATION HALF-LIVES IN A PRE-CLINICAL INFECTION MODEL.

Iordanis Kesisoglou1, Brianna M Eales2, Kimberly R Ledesma2, Paul R Merlau2, Vincent H Tam1,2, Weiqun Wang2, Michael Nikolaou1.   

Abstract

Combination therapy for treatment of multi-drug resistant bacterial infections is becoming common. In vitro testing of drug combinations under realistic pharmacokinetic conditions is needed before a corresponding combination is eventually put into clinical use. The current standard for design of such in vitro simulations for drugs with different half-lives is heuristic and limited to two drugs. To address that void, we develop a rigorous design method suitable for an arbitrary number of N drugs with different half-lives. The method developed offers substantial flexibility and produces novel designs even for two drugs. Explicit design equations are rigorously developed and are suitable for immediate use by experimenters. These equations were used in experimental verification using a combination of three antibiotics with distinctly different half-lives. In addition to antibiotics, the method is applicable to any anti-infective or anti-cancer drugs with distinct elimination pharmacokinetics.

Entities:  

Keywords:  Combination therapy; In vitro simulation; Mathematical modelling; Multi-drug resistance; Pharmacokinetics

Year:  2021        PMID: 34924641      PMCID: PMC8682276          DOI: 10.1016/j.compchemeng.2021.107540

Source DB:  PubMed          Journal:  Comput Chem Eng        ISSN: 0098-1354            Impact factor:   3.845


  21 in total

1.  Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.

Authors:  Vincent H Tam; Kai-Tai Chang; Jian Zhou; Kimberly R Ledesma; Kady Phe; Song Gao; Françoise Van Bambeke; Ana María Sánchez-Díaz; Laura Zamorano; Antonio Oliver; Rafael Cantón
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.790

Review 2.  In vitro pharmacodynamic models to determine the effect of antibacterial drugs.

Authors:  Julia Gloede; Christian Scheerans; Hartmut Derendorf; Charlotte Kloft
Journal:  J Antimicrob Chemother       Date:  2009-12-21       Impact factor: 5.790

3.  The complexity of minocycline serum protein binding.

Authors:  Jian Zhou; Brian T Tran; Vincent H Tam
Journal:  J Antimicrob Chemother       Date:  2017-06-01       Impact factor: 5.790

Review 4.  When does 2 plus 2 equal 5? A review of antimicrobial synergy testing.

Authors:  Christopher D Doern
Journal:  J Clin Microbiol       Date:  2014-06-11       Impact factor: 5.948

5.  Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options.

Authors:  Stamatis Karakonstantis; Evangelos I Kritsotakis; Achilleas Gikas
Journal:  J Antimicrob Chemother       Date:  2020-02-01       Impact factor: 5.790

Review 6.  The clinical pharmacokinetics of levofloxacin.

Authors:  D N Fish; A T Chow
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

7.  Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa.

Authors:  Brice Layeux; Fabio Silvio Taccone; David Fagnoul; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Antimicrob Agents Chemother       Date:  2010-09-07       Impact factor: 5.191

8.  Prevalence of extended-spectrum beta-lactamase-producing Gram-negative bacteria in septicaemic neonates in a tertiary care hospital.

Authors:  Amita Jain; Indranil Roy; Mahendra K Gupta; Mala Kumar; S K Agarwal
Journal:  J Med Microbiol       Date:  2003-05       Impact factor: 2.472

Review 9.  The pharmacokinetics of meropenem.

Authors:  G L Drusano; M Hutchison
Journal:  Scand J Infect Dis Suppl       Date:  1995

Review 10.  Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans.

Authors:  Jürgen B Bulitta; William W Hope; Ann E Eakin; Tina Guina; Vincent H Tam; Arnold Louie; George L Drusano; Jennifer L Hoover
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.